Reply to: ‘Severe bullous pemphigoid following Covid‐19 vaccination resistant to rituximab and successfully treated with dupilumab’ by Baffa et al.
Sign Up to like & getrecommendations! Published in 2023 at "Journal of the European Academy of Dermatology and Venereology"
DOI: 10.1111/jdv.18893
Abstract: Dear Editor, We read with interest the article by Baffa et al., who reported a case of severe bullous pemphigoid (BP) developed 10 days after the second dose of Pfizer/BioNtech BNT162b2 mRNA vaccine against Covid19,… read more here.
Keywords: rituximab successfully; bullous pemphigoid; treated dupilumab; severe bullous ... See more keywords